AbbVie (ABBV) Stock: Headed Up On Preliminary Tender Offer Results

AbbVie Inc (NYSE: ABBV) is having an overwhelmingly strong start to the trading session in the pre-market hours this morning and for good reason. The company announced the preliminary results of its modified Dutch auction tender offer. Of course, the results proved to be positive, leading to excitement among investors and sending the stock screaming … Read more

AbbVie Inc (ABBV) Stock: Gains On EMA Application And Offer

AbbVie Inc (NYSE: ABBV) is having a relatively strong start to the trading session this morning after announcing that it has submitted a marketing authorization application to the European Medicines Agency. The company also announced a “Dutch auction” tender offer that will allow the company to purchase shares from current shareholders. Of course, the news … Read more

TG Therapeutics (TGTX) Stock: More Than Doubles On Positive Data

TG Therapeutics Inc (NASDAQ: TGTX) TG Therapeutics is having an incredibly strong day in the market today. After starting the trading session off well into the green, the stock has only continued with impressive gains since the opening bell rang. Below, we’ll talk about what we’re seeing from TGTX, why, and what we’ll be watching … Read more

AbbVie (ABBV) Stock: Skyrocketing On IP Chatter | (CHRS) Stock Tanking

AbbVie Common Stock (NYSE: ABBV) | Coherus Biosciences Inc (NASDAQ: CHRS) AbbVie and Coherus Biosciences were both off to a relatively normal start in the market today. While both were trading in the green, they weren’t gaining by much. That is, until minutes ago. At the moment, ABBV is spiking and CHRS is falling apart. … Read more

Achillion Pharmaceuticals (ACHN) Climbs On Interim Odalasvir Results

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) Achillion Pharmaceuticals is having an incredible day in the market after announcing interim results from a Phase 2 study evaluating odalasvir, an NS5A inhibitor. Today, we’ll take a look at the interim data offered by the company, how the market reacted to the news, and what we can expect to … Read more

Baxalta Vs. AbbVie: Biopharma Spin-Off Battle

Abbott Laboratories (ABT) spun-off biopharmaceutical business AbbVie (ABBV) in 2013. Baxter International (BAX) must have been paying   attention. The company spun-off its own biopharmaceutical business this year. The new business is called Baxalta (BXLT). Baxalta has a market cap of $27 billion, while AbbVie has a market cap of $114 billion. Baxter and Abbott both … Read more